Printer Friendly

More Options, More Hope for Blood Cancer Patients.

After 25 years working with cancer patients, 63-year-old oncology nurse Barbara Stevens knew how scary a diagnosis could be. The grandmother of 10 underwent back surgery to stabilize a fracture, but was still experiencing painful muscle spasms after the operation. When x-rays showed additional fractures in her spine, doctors ordered additional blood tests. Stevens was diagnosed with multiple myeloma, the second most common cancer of the blood.

Multiple myeloma affects an estimated 50,000 Americans, with approximately 15,000 new cases diagnosed each year. The cancer attacks plasma cells, or white blood cells, primarily in bone marrow -- which can damage the immune system's ability to fight against infection and disease. Myeloma tumors can also spread to multiple sites, causing bone destruction and fractures. Like Stevens' case, the disease is often discovered by chance and is not noticed until it has reached an advanced stage.

"Despite advances in treatment, only 30 percent of patients with advanced multiple myeloma typically live for more than five years after diagnosis," said Dr. Paul Richardson of the Dana-Farber Cancer Institute. "So it's important for patients to have access to new medicines."

Richardson is a leading investigator for new multiple myeloma treatment options. A recent study in the New England Journal of Medicine, led by Richardson, shows multiple myeloma patients treated with Velcade had a better chance at survival compared to patients who used the standard treatment.

For the full story and a photo, go to http://www.medialinkfeatures.com/home.aspx?Story=30711

ABOUT MEDIALINK FEATURES: Medialink Features provides free, ready-to-run, non-copyrighted news features, fillers and photos to newspaper and online editors. To download copy and photos, please visit http://www.medialinkfeatures.com.

NOTE TO EDITORS: All copy and photography is available for free and unrestricted use with Medialink Features (MF) dateline attribution.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 11, 2005
Words:298
Previous Article:AuEx Ventures Inc. Acquires Nevada Silver Project.
Next Article:Kodak to Host Investor Event at Print '05.


Related Articles
NIH panel okays human gene transfer test.
New test spots cancer cells in blood.
Gift of Life.
TUMOR-REDUCTION STUDY STARTS AT CANCER CENTER.
DRUGS SHOW PROMISE FOR CANCER CURE.
BREAST CANCER RESEARCH PAYING DIVIDENDS; TWO NEW DRUGS OFFER EXCITING POSSIBILITIES, COMPLEXITIES.
UMBILICAL CORD MIRACLE?
Tracking tumors: looking for early signs of a therapy's success.
CHECKUP KNOW CANCER TREATMENT OPTIONS.
GIFTS OF BEAUTY TEENS CUT HAIR TO AID PATIENTS.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters